Enzo Biochem (ENZ) Releases Earnings Results

Enzo Biochem (NYSE:ENZ) posted its earnings results on Thursday. The medical research company reported ($0.01) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.01), Bloomberg Earnings reports. Enzo Biochem had a negative return on equity of 2.83% and a negative net margin of 2.32%.

Enzo Biochem (NYSE ENZ) traded up $0.24 during mid-day trading on Friday, reaching $9.51. The company had a trading volume of 170,000 shares, compared to its average volume of 207,257. Enzo Biochem has a 12-month low of $6.27 and a 12-month high of $12.04.

Several equities analysts recently commented on ENZ shares. BidaskClub downgraded Enzo Biochem from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Zacks Investment Research downgraded Enzo Biochem from a “buy” rating to a “hold” rating in a research report on Tuesday, August 15th. Finally, TheStreet downgraded Enzo Biochem from a “b” rating to a “c+” rating in a research report on Wednesday, September 27th.

In related news, Director Gregory M. Bortz sold 42,005 shares of the firm’s stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $9.82, for a total transaction of $412,489.10. Following the completion of the sale, the director now directly owns 292,875 shares of the company’s stock, valued at approximately $2,876,032.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP James Michael O’brien sold 22,866 shares of Enzo Biochem stock in a transaction on Friday, October 27th. The shares were sold at an average price of $10.28, for a total value of $235,062.48. Following the completion of the sale, the executive vice president now directly owns 34,886 shares of the company’s stock, valued at $358,628.08. The disclosure for this sale can be found here. Insiders have sold a total of 191,398 shares of company stock valued at $1,925,292 over the last ninety days. Insiders own 8.90% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Enzo Biochem (ENZ) Releases Earnings Results” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/08/enzo-biochem-enz-releases-earnings-results.html.

Enzo Biochem Company Profile

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Earnings History for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply